N
Narinder S. Shargill
Researcher at Harvard University
Publications - 4
Citations - 7348
Narinder S. Shargill is an academic researcher from Harvard University. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 1, co-authored 1 publications receiving 6903 citations.
Papers
More filters
Journal ArticleDOI
Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance
TL;DR: A role for TNF-alpha in obesity and particularly in the insulin resistance and diabetes that often accompany obesity is indicated.
Journal ArticleDOI
A multicenter, prospective, single-arm clinical investigation of a modified staged treatment algorithm using the AeriSeal system - The STAGE trial.
T. David Koster,Ralf Eberhardt,Ralf-Harto Huebner,Arschang Valipour,Felix J.F. Herth,Karin Klooster,Narinder S. Shargill,Sri Radhakrishnan,Dirk-Jan Slebos +8 more
TL;DR: In this article , a staged and lower-dose AeriSeal was used to achieve lung volume reduction in patients with severe COPD and emphysema who are not eligible for valve treatment.
Proceedings ArticleDOI
CONVERT Trial: Collateral ventilation conversion by closure of fissure defect with AeriSeal Foam for BLVR with Zephyr valves
M Bezzi,G. Levi,Kaid Darwiche,T. Egenod,Nolwenn Guibert,D. Franzen,Felix J.F. Herth,Dirk-Jan Slebos,A. Kirk,A. Yang,D. Mchugh,Narinder S. Shargill,Samuel V. Kemp,Pallav L. Shah +13 more
TL;DR: The CONVERT study as discussed by the authors showed that AeriSeal Foam (AF) can safely and effectively occlude collateral channels and convert a CV+ lung lobe to having little to no collateral ventilation.